Edwards Lifesciences, a global leader in structural heart innovations, has introduced its next-generation transcatheter heart valve platform in India. This launch marks a major milestone in treating aortic stenosis, especially for patients who cannot undergo open-heart surgery. The new therapy offers a minimally invasive, durable solution designed to support long-term health and quality of life.
Addressing the Urgency of Aortic Stenosis
Aortic stenosis is a progressive condition linked to aging and caused by calcification of the aortic valve, which restricts blood flow from the heart. Once symptoms appear, nearly 50% of patients die within two years without timely intervention. The Global Burden of Disease study highlights that in India, severe calcific non-rheumatic aortic stenosis contributes significantly to cardiovascular deaths. This underscores the urgent need for early diagnosis and effective treatment.
Innovative Valve Features
As per the press release, the latest-generation balloon-expandable transcatheter heart valve incorporates proprietary calcification-resistant tissue technology. This innovation prevents calcium buildup on the valve leaflets, a leading cause of valve deterioration and reintervention. Additional features include:
- Dry tissue storage, which simplifies hospital workflows
- A taller, textured outer sealing skirt, which reduces paravalvular leak
Proven Clinical Benefits
Clinical data comparing this platform with its predecessors show significant improvements within one year, including:
- Lower all-cause mortality
- Reduced paravalvular leak
- Fewer life-threatening bleeding events
- Rare need for reintervention
Long-term studies further demonstrate the valve’s durability:
- 99.3% freedom from structural valve deterioration (SVD) at 7 years
- Significantly lower rates of SVD, reoperations, and all-cause reinterventions at 8 years compared to valves without calcification-resistant tissue
Lifetime Management Approach
Edwards Lifesciences emphasizes a “lifetime management” strategy that plans a patient’s entire treatment journey from the first procedure. Central to this approach is the valve-in-valve technique, which allows physicians to implant a new transcatheter valve inside an existing one, or within a degenerated surgical valve, when needed. This ensures a minimally invasive pathway and reduces the need for repeat open-heart surgery.
Indian Cardiologists Welcome the Launch
Renowned Indian cardiologists shared their enthusiasm for the new technology:
- Dr. Ravinder Singh Rao, Lilavati Hospital, Mumbai: “This more durable and long-lasting transcatheter heart valve will allow us to safely and effectively treat younger patients with severe aortic stenosis.”
- Dr. G. Sengottuvelu, Apollo Hospital, Chennai: “Durability is the key for evaluating any transcatheter heart valve. With its strong clinical record, this launch will support long-term disease management.”
- Dr. A. B. Gopalamurugan, MGM Healthcare, Chennai: “We have waited a long time for this technology to reach India. Patients here can now access best-in-class transcatheter heart valve therapy within their own country.”
Edwards Lifesciences’ Commitment to India
Mr. Parameswaran Nair, Country Leader of India and Southeast Asia at Edwards Lifesciences, said:
“At Edwards Lifesciences, we are deeply committed to pioneering innovations that redefine care for structural heart disease. By integrating minimally invasive techniques with exceptional durability, we are enhancing survival and quality of life for patients with aortic stenosis in India. This milestone demonstrates our dedication to empowering clinicians, expanding access to care, and meeting the needs of younger patients requiring lifelong treatment strategies.”
Looking Ahead
As India faces rising rates of cardiovascular disease and an aging population, Edwards Lifesciences continues to partner with clinicians and healthcare providers to expand access to transformative heart therapies. The company remains focused on helping patients live longer, healthier, and more active lives through cutting-edge cardiovascular solutions.